Tatiana Novobrantseva
Chief Scientific Officer NextPoint Therapeutics
Tatiana Novobrantseva is the Chief Scientific Officer at NextPoint Therapeutics. Most recently she served as the CSO of Immuno-oncology at Moderna. In the prior role, she co-founded Verseau Therapeutics and served as CSO, guiding programs from target identification to an advanced novel therapeutics pipeline. Tatiana also consulted on drug development program for various companies throughout the years. At Jounce, she directed programs on immune system reactivation against cancer. Tatiana held roles at Alnylam and Biogen, uncovering the critical role of B cells in fibrosis, advancing siRNA delivery, and leading a dendritic cell cancer vaccine initiative.
She earned her Ph.D. in B cell immunology from the University of Cologne in Germany in the Laboratory of Klaus Rajewsky. She holds a Diploma in Engineering in Physics and a Master’s degree in Molecular Biology from the Moscow Institute of Physics and Technology.
Seminars
- B7-H7 is broadly upregulated across multiple high-prevalence malignancies with significant unmet need, while maintaining a restricted and favorable expression profile in healthy tissue
- NextPoint lead T-cell engager, NPX372, features an optimized molecular architecture specifically designed to achieve an expansive therapeutic index
- Leveraging a biomarker-driven patient selection strategy and validated preclinical safety data, a streamlined Phase I clinical program has been launched
- Using a SWOT analysis approach, what are the strengths, weaknesses, opportunities and threats of bispecifics/ multispecifics compared to other drug modalities?
- In which cases are bispecifics/multispecifics being prioritized for autoimmune and immunology versus oncology?
- What datapoints are being assessed when it comes to bispecifics/multispecifics from a data package perspective for approval and backing from pharma?
- What data is lacking across the board for bispecifics/multispecifics?
- How are novel versus derisked targets being assessed, and what weighting/value is placed on safety and efficacy data, versus other data points?
- What stimulates interest around bispecific/multispecific assets versus platform technologies that generate target, construct and format menus?
